MARKET

BHVN

BHVN

Biohaven
NYSE
11.03
-0.25
-2.22%
After Hours: 11.03 0 0.00% 19:29 12/16 EST
OPEN
11.31
PREV CLOSE
11.28
HIGH
11.65
LOW
10.69
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
44.28
52 WEEK LOW
7.48
MARKET CAP
1.46B
P/E (TTM)
-1.4519
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BHVN last week (1208-1212)?
Weekly Report · 1d ago
Biohaven jumps on early-stage data for antibody drug conjugate combo
Seeking Alpha · 5d ago
Biohaven presents data for BHV-1510 at ESMO
TipRanks · 5d ago
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
Barchart · 6d ago
Weekly Report: what happened at BHVN last week (1201-1205)?
Weekly Report · 12/08 10:09
Biohaven Ltd. (BHVN) Receives a Rating Update from a Top Analyst
TipRanks · 12/05 12:41
Biohaven downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 12/03 11:10
Weekly Report: what happened at BHVN last week (1124-1128)?
Weekly Report · 12/01 10:05
More
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Webull offers Biohaven Ltd stock information, including NYSE: BHVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BHVN stock methods without spending real money on the virtual paper trading platform.